Meta Plunges, Ford Slides, Eli Lilly Gains After Boosting Sales View
On this episode of Stock Movers:
- Meta (META US) shares plunge after the company raised its spending outlook for the year, driven by its AI strategy and higher component pricing. The social media giant projected full-year capital expenditures of $125 billion to $145 billion, exceeding analysts' estimates, and is kicking off a bond sale of between $20 billion and $25 billion in debt.
- Ford (F) shares slide. The automaker raised its full-year profit outlook due to demand for high-margin pickups and SUVs, but warned of pressure from an unexpected rise in commodity costs. The company expects to earn as much as $10.5 billion before interest and taxes this year, and also expects a $2 billion profit hit from rising commodity prices such as steel and aluminum.
- Eli Lilly (LLY) shares gain. The company raised its annual sales and profit forecast due to high demand for obesity medications and its new weight-loss pill. The company now sees 2026 sales rising to as much as $85 billion and 2026 profits in the range of $35.50 a share to $37 a share.
See omnystudio.com/listener for privacy information.
More description
On this episode of Stock Movers:
- Meta (META US) shares plunge after the company raised its spending outlook for the year, driven by its AI strategy and higher component pricing. The social media giant projected full-year capital expenditures of $125 billion to $145 billion, exceeding analysts' estimates, and is kicking off a bond sale of between $20 billion and $25 billion in debt.
- Ford (F) shares slide. The automaker raised its full-year profit outlook due to demand for high-margin pickups and SUVs, but warned of pressure from an unexpected rise in commodity costs. The company expects to earn as much as $10.5 billion before interest and taxes this year, and also expects a $2 billion profit hit from rising commodity prices such as steel and aluminum.
- Eli Lilly (LLY) shares gain. The company raised its annual sales and profit forecast due to high demand for obesity medications and its new weight-loss pill. The company now sees 2026 sales rising to as much as $85 billion and 2026 profits in the range of $35.50 a share to $37 a share.
See omnystudio.com/listener for privacy information.
Listen elsewhere
Available Results
Generated results are saved to your library for reuse and search.